Virtual ACC 2020 | TAILOR-PCI: Gene-Based Prescribing of Clopidogrel Does Not Change Outcomes

This very interesting work leaves us with a sour taste in our mouth, as it failed to meet its primary endpoint. Using genotype to individualize treatment with a P2Y12 inhibitor in patients with acute coronary syndrome or stable patients after a scheduled angioplasty compared with conventional treatment with clopidogrel does not reduce the risk of ischemic events at 12 months. This is another nice theory that crashes and burns against reality.

TAILOR PCR | Clopidogrel

Many people expected this work to provide a definitive answer on the efficacy of knowing patient genotype, after the publication of POPular Genetics a few months back showing the noninferiority of a genotype-guided strategy vs. treatment with ticagrelor or prasugrel, but without such information.

At 1 year, there was a 34% reduction in the combined endpoint (cardiovascular death, infarction, stroke, definite or probable stent thrombosis, and severe recurrent ischemia) with a strategy guided by genotype (basically, the identification of a CYP2C19 loss-of-function allele) compared with a conventional strategy with clopidogrel (4.0% vs. 5.9%; hazard ratio [HR]: 0.66; 95% confidence interval [CI]: 0.43-1.02). Such 34% is not statistically significant, since the target was 50%.

Original title: TAILOR PCI: tailored antiplatelet initiation to lessen outcomes due to decreased clopidogrel response after percutaneous coronary intervention.

Reference: Pereira N et al. Presentado en forma virtual en el ACC 2020.

Would you like to receive a weekly summary of the most recent scientific articles?

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

(Visited 1 times, 1 visits today)